Clinical trials: Hormone Disturbance
Obese But Otherwise Healthy Participants
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body. The study has two parts: Part 1 will measure drug levels in healthy adults after taking CRB-913 tablets, and Part 2 will…
- Trial name
- CANYON-1 (NCT07310901)
- Testing
- CRB-913
- Where
- 15 sites in United States
- Volunteers
- 254 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Pancreatic Carcinoma
Preoperative Biliary Drainage in Resectable Pancreatic or Periampullary Cancer
The purpose of this study is to demonstrate that preoperative biliary drainage using self-expanding metal stents (SEMS) does not negatively impact overall surgical outcomes in patients undergoing pancreaticoduodenectomy for…
- Trial name
- NCT01774019
- Testing
- WallFlex™ Biliary RX Fully Covered/Uncovered Stent System
- Where
- 11 sites in United States, Australia and 7 more
- Volunteers
- 284 people
- Sponsor
- Boston Scientific Corporation
Diabetes
Protocol for the Evaluation of Dario™ BGMS Performance at Elevated Altitude
The purpose of this study is to assess the performance of the Dario Blood Glucose Monitor (BGMS), at elevated altitudes, by obtaining whole blood fingerstick samples from individuals and analyzing the blood on the Dario Blood…
- Trial name
- NCT02352298
- Testing
- Dario Blood Glucose Monitoring System, YSI Analyzer
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- LabStyle Innovations Ltd.
Pancreatic Cancer, Metastatic Pancreatic Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Pancreatic cancer is difficult to diagnose early. By the time people have been diagnosed, the cancer has usually spread to other parts of the body (metastatic).
- Conditions
- Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT07409272
- Testing
- Setidegrasib, Oxaliplatin, Leucovorin
- Where
- 79 sites in United States, China and 4 more
- Volunteers
- 614 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Obesity With Diabetes, Overweight With Diabetes
Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: Percent change in body weight Change in hemoglobin A1c (HbA1c)
- Trial name
- KaiNETIC-2 (NCT07284901)
- Testing
- Ribupatide
- Where
- 173 sites in United States, Argentina and 9 more
- Volunteers
- 1,270 people
- Sponsor
- Kailera
Chronic Kidney Disease
RAYALDEE Non Interventional Study (NIS) on Effectiveness in ND-CKD SHPT Patients
The overall study objective is to collect real-world data on the safety and effectiveness of ERC to gradually increase 25D to the level required by Stage 3 and 4 CKD patients.
- Trial name
- PORTRAY (NCT05460234)
- Where
- 16 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Vifor (International) Inc.
Malignant Solid Tumour, Ovarian Cancer
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
Overall Design: This is a multicenter, open-label, Phase 1/2 study which will be conducted in three arms (as described below). Each arm will be conducted in two parts: a Phase 1 part which will include dose escalation and a Phase…
- Conditions
- Malignant Solid Tumour, Ovarian Cancer, Triple Negative Breast Cancer, Advanced Melanoma
- Trial name
- NCT01618136
- Testing
- E7449 alone, E7449 plus TMZ, E7449 plus carboplatin and paclitaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 41 people
- Sponsor
- Eisai Limited
Diabetes Mellitus Type 2
A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus
To assess the impact on glucose control by inhaled insulin in patients with type 2 diabetes who are not well controlled on 2 or more oral anti-diabetic agents
- Trial name
- NCT00282971
- Testing
- Inhaled Insulin (Exubera), Standard of Care
- Where
- 64 sites in Canada, France and 5 more
- Volunteers
- 354 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 1
A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of multiple doses of PF-06342674. Several dose levels will be evaluated.
- Trial name
- NCT02038764
- Testing
- PF-06342674 Dose A, PF-06342674 Dose B, PF-06342674 Dose C
- Where
- 21 sites in United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Chronic Kidney Disease, Type 1 Diabetes Mellitus
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
Researchers are looking for a better way to treat people with chronic kidney disease (CKD), a progressive decrease in the kidneys' ability to work properly, and type 1 diabetes.
- Trial name
- FINE-ONE (NCT05901831)
- Testing
- Finerenone
- Where
- 79 sites in United States, Canada and 7 more
- Volunteers
- 242 people
- Sponsor
- Bayer
Macular Edema
A Study to Evaluate the Effectiveness of Intravitreal Aflibercept in Patients With Diabetic Macular Edema and/or Macular Edema Secondary to Retinal Vein Occlusion, Which Either Have or Have Not Been Pretreated for Their Disease
AURIGA is designed to collect data from routine clinical practice on the effectiveness and utilization of intravitreal aflibercept in the treatment of visual impairment due to diabetic macular edema (DME) or macula edema…
- Trial name
- AURIGA (NCT03161912)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- 11 sites in China, Egypt and 9 more
- Volunteers
- 2,481 people
- Sponsor
- Bayer
Endometrial Cancer
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
- Trial name
- NCT06463028
- Testing
- Sapanisertib, Serabelisib, Paclitaxel
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- Faeth Therapeutics
Type 2 Diabetes Mellitus
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus. In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and…
- Trial name
- NCT01677299
- Testing
- EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the pharmacodynamic (the effect of the investigated drug on the body) response of Faster acting insulin aspart (FIAsp) in subjects with type 1 diabetes.
- Trial name
- NCT02033239
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Novo Nordisk A/S
Secondary Hypogonadism
Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function
To determine and compare the pharmacokinetics (PK) of a single dose of 25 mg Androxal in overweight male subjects with various stages of renal impairment and in volunteers with normal renal function.
- Trial name
- NCT01923857
- Testing
- Androxal 25 mg
- Where
- 2 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Repros Therapeutics Inc.
Diabetes Mellitus
Pioglitazone Study of Triglyceride Changes in Subjects With Type 2 Diabetes After Conversion From Rosiglitazone.
The purpose of this study is to measure the triglyceride changes in subjects with type 2 diabetes mellitus taking pioglitazone, once daily (QD), following treatment conversion from rosiglitazone.
- Trial name
- COMPLEMENT (NCT00672919)
- Testing
- Pioglitazone
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Takeda
Type 2 Diabetes
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Liraglutide injection is a glucagon-like peptide-1 (GLP-1) analogue that activates the cyclic adenosine monophosphate (cAMP) and mitogen-activated protein kinase (MAPK) pathway by binding to the GLP-1 receptor (GLP-1R),thus,it…
- Trial name
- NCT04373967
- Testing
- Victoza®., Metformin Hydrochloride, TQZ2451
- Where
- 46 sites in China
- Volunteers
- 424 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Hypoparathyroidism, Endocrine System Diseases
Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
This study is investigating the safety and efficacy of eneboparatide (AZP-3601) in patients with chronic hypoparathyroidism (cHP).
- Conditions
- Chronic Hypoparathyroidism, Endocrine System Diseases, Parathyroid Diseases
- Trial name
- CALYPSO (NCT05778071)
- Testing
- eneboparatide
- Where
- 54 sites in United States, Canada and 11 more
- Volunteers
- 165 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hypercholesterolemia, Coronary Heart Disease
Assessment of the Efficacy of Rosuvastatin in Patient Groups With a Dissimilar Risk Profile in an Observational Study (HEROS)
In an observational multi-centre study (HEROS), the effects of starting treatment with rosuvastatin were assessed, on low-density lipoprotein cholesterol (LDL-C) goal achievement, in patients with a dissimilar high-risk profile…
- Conditions
- Hypercholesterolemia, Coronary Heart Disease, Peripheral Vascular Disease, Cerebrovascular Accident
- Trial name
- HEROS (NCT00660764)
- Testing
- Rosuvastatin
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
Novo Nordisk is developing a combination therapy with the investigational drug NNC0480-0389 and an already approved medicine called "semaglutide" for the treatment of type-2 diabetes (T2D).
- Trial name
- NCT05153564
- Testing
- Semaglutide 1.34 mg/mL, Semaglutide 3.0 mg/mL, NNC0480-0389 10 mg/mL
- Where
- Germany
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S